Overview of the Indian Clinical Trials Market

 

Market Size and Growth:

The Indian clinical trials market is booming, currently valued at USD 1.55 billion and projected to reach USD 8.36 billion by 2029, growing at a CAGR of 8.64%. This impressive growth is driven by several factors:

• Large and diverse patient population: With over 1.3 billion people, India offers a vast pool of participants for diverse clinical trials.
• Cost-effectiveness: Conducting trials in India is significantly cheaper compared to Western countries, attracting global pharmaceutical companies.
• Regulatory ease: Streamlined approval processes and recent amendments to the New Drugs and Clinical Trials (NDCT) Rules have simplified the conduct of trials.
• Rising R&D investment: Both domestic and international pharmaceutical companies are increasing R&D spending in India, leading to more clinical trials.
• Skilled workforce: A growing pool of scientists, doctors, and research professionals ensures high-quality trial execution.

Key Players:

Several key players contribute to the success of clinical research:

• Domestic pharmaceutical companies: Cipla, Sun Pharma, and Dr. Reddy's Laboratories are actively involved in clinical trials.
• International pharmaceutical companies: Global giants like Pfizer, Novartis, and Roche are increasingly conducting trials in India.
• Contract research organizations (CROs): International CROs like Parexel and Iqvia, along with domestic players like Syngene International and Acumen Research, provide critical support.
• Clinical research sites: Leading hospitals, medical colleges, and research institutes form the backbone of the clinical trial infrastructure.

Number of People Employed:

Estimates suggest over 300,000 people are directly or indirectly employed in the Indian clinical trials market. This includes researchers, clinicians, nurses, data analysts, project managers, and administrative personnel. The demand for skilled professionals is expected to rise further, creating significant job opportunities.

Key Trends:

• Decentralized clinical trials: Increasingly popular, reaching patients in rural areas and improving access to trials.
• Focus on therapeutic areas: Oncology, diabetes, infectious diseases, and cardiovascular diseases are leading areas for clinical trials.
• Adoption of digital technologies: AI-powered platforms, telemedicine, and e-consent are enhancing trial efficiency and data management.
• Increasing patient participation: Awareness campaigns and improved ethical practices are boosting patient engagement.
• Focus on quality and compliance: Stringent regulatory oversight and international collaborations are improving trial quality and safety.
• India holds a significant position in the global clinical trials market, accounting for around 8% of global trial activity.
• The government is actively promoting clinical research through initiatives like the National Clinical Research Network.
• Ethical considerations and patient protection remain crucial areas of focus to ensure responsible and sustainable growth in the market.

The Indian clinical trials market presents a promising and dynamic landscape for research and development. Understanding the key trends and challenges will be crucial for both domestic and international players to navigate this rapidly evolving market effectively.

Overview of China's Clinical Trials Market

 

Market Size and Growth:

• The Chinese clinical trials market is on a meteoric rise, currently valued at USD 40 billion and projected to reach USD 82 billion by 2028, with a CAGR of 14.9%.
• This impressive growth is fueled by:
• Clinical trials: Involve testing the drug on human volunteers in a series of meticulously designed phases:
  • A massive and increasingly affluent population (1.4 billion+) presenting a huge patient pool.
  • Rising R&D expenditure in pharma and biotechnology, with China becoming a global R&D hub.
  • Government initiatives to streamline regulations and incentivize clinical trials.
  • Rapidly growing healthcare infrastructure and skilled clinical research professionals.

Key Players:

• Domestic pharmaceutical companies: Local giants like Huahai and Zheijiang Hisun control a significant share, competing with global players like Roche and Merck.
• International pharmaceutical companies: Increasingly conducting trials in China due to the potential market size and faster approval processes.
• Contract research organizations (CROs): Both international (IQVIA, Parexel) and domestic (WuXi AppTec, CRO Clinical Trial Center) play crucial roles.
• Clinical research sites: Over 29,000 hospitals and 1 million+ independent clinics offer diverse sites, including top academic medical centers.

Number of People Employed:

• Estimates suggest over 1.5 million people work in the clinical trials market directly or indirectly.
• This includes researchers, clinicians, nurses, data analysts, project managers, and administrative personnel.
• The demand for skilled professionals is high, creating significant job opportunities.

Key Trends:

• Decentralized clinical trials: Gaining traction to improve patient access and trial diversity, reaching beyond major cities.
• Focus on innovative therapies: China holds a prominent position in gene therapy and cell therapy trials, alongside traditional drug categories.
• Adoption of digital technologies: Telemedicine, AI-powered platforms, and e-consent are increasingly utilized for enhanced efficiency and data management.
• Data sharing and collaboration: Government initiatives promote data sharing platforms and international partnerships to drive research.
• Emphasis on patient-centricity: Patient awareness, engagement, and informed consent are becoming increasingly important.

Additional Points:

• China accounts for nearly 28% of global clinical trial activity, showcasing its global significance.
• The focus is shifting towards high-value trials in specialized areas like oncology, rare diseases, and precision medicine.
• Intellectual property and data security remain considerations for foreign companies conducting trials in China.

China's clinical trials market offers immense potential and is rapidly evolving. Navigating the complexities and staying updated on the latest trends will be crucial for success in this dynamic landscape.

European Medical Agency to increase fees upto 1.7 %

There would be an increase in fees upto 1.7 % from April 1^st 2018 as mentioned in the notification of Commission Regulation (EU) No 2018/471 (amending Council Regulation (EC) No 297/95), the fees however would be implemented for all activities carried out by the agency except pharmacovigilance. Apart from Pharmacovigilance the agency has also exempted fees ofMicro Small or Medium Sized Enterprise, Orphan Medicinal Products, Medicinal Products for Paediatric Use, Advanced Therapy Medicinal Productsetc… Detailed information on has been provided on an explanatory note.

The agency every year revises its fees as per the statistical data from EUROSTAT (European Union’s statistical office), the current revision is made in accordance with the inflation rate for 2017.

Reference:

1.       Explanatory note on general fees payable to the European Medicines Agency

http://www.ema.europa.eu/docs/en_GB/document_library/Other/2018/03/WC500246428.pdf

2.       COMMISSION REGULATION (EU) 2018/471 of 21 March 2018

http://www.ema.europa.eu/docs/en_GB/document_library/Other/2018/03/WC500246427.pdf

Brought to you by:

Cliniminds (www.cliniminds.com),leader in Pharmacovigilance & Clinical research training and consulting 

Clinimindsoffers ‘Hands On’ training case processing on ORACLE Argus Safety and other safety databases. Our students are entitled for free DIA membership.